louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05046574: A Study to Evaluate Animal-assisted Therapy in Stroke Rehabilitation
Official title: Integrating Animal-assisted Therapy in Stroke Rehabilitation: a Randomized Controlled Trial Assessing the Impact on Psychological State and Functional Recovery of Patients, as Well as Wellbeing of Therapy Dogs
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Stroke
Lead sponsor: Mayo Clinic
Sponsor class: OTHER
Collaborators: name: Purina Petcare
First posted: 2021-09-16
Enrollment: 52
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: The investigators hypothesize that the presence of a Mayo Clinic certified therapy dog will provide additional benefits above typical treatment for patients currently enrolled in the Mayo Clinic Stroke Rehabilitation Unit.

Detailed description: The objectives of this study are to measure the effects of a therapy dog embedded in stroke rehabilitation sessions on the patients' functional recovery, depression, anxiety, motivation, and quality of life.

Eligibility criteria: Inclusion Criteria:

* Patient must be 18 years of age or older.
* Patient must be in the comprehensive in-patient stroke rehabilitation program.
* Patient must have a stroke from any cause.
* Patients must be able and willing to give informed consent.
* Patients must be able to speak English as the questionnaires being used are only available in English.

Exclusion Criteria:

* Patient who has a pacemaker.
* Patient who is pregnant.
* Patient who is deemed inappropriate to the study by the medical professional.
* Patient who is unable to give informed consent.
* Patient who is unable to speak English.

Primary outcomes:
measure: Change in Anxiety
timeFrame: Baseline through inpatient stay, an average of 2 weeks.
measure: Change in Depression
timeFrame: Baseline through inpatient stay, an average of 2 weeks.
measure: Change in Quality of Life Outcomes
timeFrame: Baseline through inpatient stay, an average of 2 weeks.
measure: Change in motivation
timeFrame: Baseline through inpatient stay, an average of 2 weeks.
measure: Change in overall functional recovery
timeFrame: Baseline through inpatient stay, an average of 2 weeks.
Secondary outcomes:
Other outcomes:
Locations:
city: Rochester
country: United States
facility: Mayo Clinic in Rochester
state: Minnesota
Study officials:
affiliation: Mayo Clinic
name: Arya Mohabbat, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02217774: MGUIDE MORE Dental Implant Planning System- Clinical Accuracy Study
Official title: MGUIDE MORE Dental Implant Planning System- Clinical Accuracy Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Focus of Study: Computer-Aided Design/Instrumentation
Keywords: Computer-Aided Design/instrumentation
Cone-Beam Computed Tomography
Dental Implant
MGuide
Lead sponsor: Rambam Health Care Campus
Sponsor class: OTHER
Collaborators: name: MIS Implant Technologies, Ltd
First posted: 2014-08-15
Enrollment: 10
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: The aim of the present study is to assess the accuracy of MGUIDE MORE System (MGS), consisting of MGUIDE MORE software, MGUIDE MORE surgical kit and MGUIDE MORE template by evaluating the difference between planned and actual implant positions on pre- and post-operative CBCTs.

Detailed description: Patients, attending the Department of Periodontology at the Rambam School of Graduate Dentistry, who are scheduled for implant therapy, will be screened for the study. Patients will be referred for CBCT of the upper/lower jaw as appropriate. DICOM data of the patient will be uploaded to MGUIDE software and used for diagnosis and treatment planning of the case. Surgery will be performed using MGUIDE MORE template and MGUIDE MORE surgical kit. Pre-operative and post-operative CBCT will be used for assessment of the difference between planned and actual implant positions.

Eligibility criteria: Inclusion Criteria:

* Signed and dated inform consent form.
* Age between 18+.
* Patient expresses his wish to restore the missing tooth/teeth with dental implants.
* Patient is examined and found suitable for implant therapy
* Patient can open mouth sufficiently for preparation and placement of dental implants using the contra-angle handpiece and drills.
* CBCT is required for proper diagnosis and treatment planning.

Exclusion Criteria:

-

Primary outcomes:
measure: Deviation from planning
timeFrame: 0-14 days after implant placement
Secondary outcomes:
Other outcomes:
Locations:
city: Haifa
country: Israel
facility: Rambam Health Care Campus
Study officials:
affiliation: Rambam Health Care Campus
name: Jacob Horwitz, DMD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Horwitz J, Zuabi O, Machtei EE. Accuracy of a computerized tomography-guided template-assisted implant placement system: an in vitro study. Clin Oral Implants Res. 2009 Oct;20(10):1156-62. doi: 10.1111/j.1600-0501.2009.01748.x. Epub 2009 Jun 10.
Clinical trial NCT06815874: Recurrence of Thromboembolic Venous Disease of Atypical Location (RUSE)
Official title: Recurrence of Thromboembolic Venous Disease of Atypical Location
Study type: OBSERVATIONAL
Overall status: ACTIVE_NOT_RECRUITING
Conditions: Venous Thromboembolism
Lead sponsor: University Hospital, Brest
Sponsor class: OTHER
First posted: 2025-02-10
Enrollment: 300
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Any patient with documented atypical localisation of VTE

Brief summary: RUSE is a retrospective data-based study designed to assess the frequency, characteristics and phenotype of documented recurrences of thromboembolic venous disease in atypical locations.


Eligibility criteria: Inclusion Criteria:

* All patients over 18,
* Affiliated to "sécurité sociale"
* Having at least one episode of atypical localisation of VTE at Brest University Hospital

Exclusion Criteria:

* Patients under legal protection
* Minors
* Refusal to participate

Primary outcomes:
measure: Documented recurrence after previous VTE in atypical localisations
timeFrame: 01/01/2005 to 01/11/2024
Secondary outcomes:
Other outcomes:
Locations:
city: Brest
country: France
facility: Chu Brest
Study officials:
References:
Clinical trial NCT00647374: Assessment of Cortical Plasticity Following Short Term Limb Immobility
Official title: Assessment of Cortical Plasticity Following Short Term Limb Immobility
Study type: OBSERVATIONAL
Overall status: SUSPENDED
Conditions: Fracture
Lead sponsor: Hadassah Medical Organization
Sponsor class: OTHER
First posted: 2008-03-31
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: patients with wristfracture

Brief summary: The proposed project will study the consequence of short term limb immobility on the patterns of brain activity using functional imaging (fMRI)


Eligibility criteria: Inclusion Criteria:

* wrist fracture.
* Fit for MRI scanning.

Exclusion Criteria:

* Unwillingness to sign informed consent.
* Neurological disease
* s/p fractures

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Jerusalem
country: Israel
facility: Hadassah Medical Organization.
Study officials:
References:
Clinical trial NCT06906874: Activated Charcoal Use in Chronic Kidney Disease Patients
Official title: Efficacy and Safety of Activated Charcoal on Mineral Bone Disorder in Chronic Kidney Disease Patients
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: PHASE2
Conditions: End Stage Renal Disease (ESRD)
CKD 5D, Hemodialysis
CKD-MBD - Chronic Kidney Disease Mineral and Bone Disorder
Lead sponsor: Mansoura University
Sponsor class: OTHER
First posted: 2025-04-02
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Hyperphosphatemia management is initially based on restricting dietary phosphorus intake. Hyperphosphatemia is almost always seen in patients on dialysis and may contribute to progressive vascular calcification. Considering that activated charcoal is generally well-tolerated and may have a favorable side effect profile compared to conventional phosphate binders, it presents a promising alternative. Until now, no clinical trial has primarily investigated the effect of activated charcoal on hyperphosphatemia in dialysis patients.


Eligibility criteria: Inclusion Criteria:

1. Adult aged ≥18 years with ESRD.
2. Patients who had been on stable maintenance hemodialysis (3 times weekly) for at least 6 months.
3. Patients receiving phosphate binders according to standard protocols established by kidney disease: Improving Global Outcomes (KDIGO).

Exclusion Criteria:

1. Severely malnourished (as diagnosed by the department's dietitian).
2. Treated with overnight dialysis.
3. Primary hyperparathyroidism or persistent serum levels of intact parathyroid hormone greater than 800 pg/mL.

Primary outcomes:
measure: Serum phosphorus levels
timeFrame: 8 weeks
Secondary outcomes:
measure: The percentage of patients who achieved decreasing at least 3 points in The Worst Itching Intensity Numerical Rating Scale (WI NRS)
timeFrame: 8 weeks
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT04976374: Analgesic Protocol With Gabapentin Dexmedetomidine For Postoperative Pain Managment
Official title: A Multimodal Analgesic Protocol With Gabapentin Dexmedetomidine For Postoperative Pain Managment After Modified Radical Mastectomy Surgery: A Randomized Placebo-Controlled Study
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Analgesia
Lead sponsor: National Cancer Institute, Egypt
Sponsor class: OTHER
First posted: 2021-07-26
Enrollment: 30
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: Assessment of quality of post mastectomy analgesic protocol of Gabapentin and Dexmedetomedine in a placebo-controlled study

Detailed description: Assessment of quality of post mastectomy analgesic protocol of Gabapentin and Dexmedetomedine in a placebo-controlled study.

Dexmedetomidine is a highly selective X2 adrenergic receptor aganist; it has anxiolytic, sedative, analgesic and sympathdytic properties without significant respiratory depressant effects. Research evidence has shown that this drug protects the body (including heart, nerves, etc.) against ischemia and hypoxic injury. Therefore, dexmedetomidine can be one of the best options for reducing pain after surgery.

Gabapentin, a structural analog of gamma aminobutyric acid, is used as an anticonvulsant drug since 1993. In addition it has been effective in neuropathic pain, diabetic neuropathy and reflex sympathetic dystrophy. It acts through binding to the X-2-5 subvnits of voltagegated calcium ion channels and preventing the central sentization and hyperalgesia. Gabapentin has demonstrated to inhibit the development and establishment of hyperalgesia and secondry allodynia in human volunteers.

Gabapentin may also decrease postoperative obioid requirement through preventing the tolerance development. Furthermore, it has minimal or no effect on gastric mucosa, renal function, and platelets count or activity in the perioperative period to be prefer over nonsteroidal anti-inflammatory drugs.

The Combination of both drugs will be tested for potentiation of post-operative analgesia and decrease of opioid consumptions

Eligibility criteria: Inclusion Criteria:

* adult female patients below 65 years of age scheduled for modified radical mastectomy surgery, American society of Anesthesiologists(ASA) physical status I-II

Exclusion Criteria:

* known allergy to study drugs; patients already taking oral gabapentin, knal or hepatic defunction, current treatment with narcotics, antihypertensives, benzodiazepines, X2 agonists, antiepileptics and antipsychotics

Primary outcomes:
measure: Post operative morphine consumption
timeFrame: 24 hours
Secondary outcomes:
measure: Post operative VAS score
timeFrame: 24 hours
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: NCI Egypt
Study officials:
References:
Clinical trial NCT00817674: Sleep Disturbances as a Non-traditional Risk Factor in CKD-Actigraphy
Official title: Sleep Disturbances as a Non-traditional Risk Factor in CKD-Wrist Actigraphy
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Chronic Kidney Disease
Sleep Loss
Keywords: CKD
Kidney Disease
poor sleep
CKD progression
Lead sponsor: University of Chicago
Sponsor class: OTHER
Collaborators: name: University of Illinois at Chicago
name: Case Western Reserve University
First posted: 2009-01-06
Enrollment: 353
Sex: ALL
Minimum age (years): 21
Maximum age (years): 74
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: CKD subjects; healthy volunteers

Brief summary: To test if usual at home night time sleep duration as measured with activity monitors and questionnaires will predict changes in kidney function as measured by kidney filtration rate and of cardiovascular function as measured by C-reactive protein in the blood. The study will explore the role of decreased sleep time or decreased sleep quality as a non-traditional risk factor for the progression of CKD and for the development of cardiovascular disease in CKD.


Eligibility criteria: Inclusion Criteria:

* Mild to Moderate CKD
* Healthy controls age and gender matched to CKD subjects
* Regular bedtimes of at least 6h/night, sedentary lifestyle

Exclusion Criteria:

* Diabetes
* Current or previous dialysis for more than 1 month
* Uncontrolled hypertension
* Heart failure
* Liver disease
* HIV
* Hemoglobin \< 10.5 g/dl
* Treatment with EProcrit, Epogen, or Aranesp
* Bone or organ transplant,
* Use of immunosuppressive drugs within past 6 months
* Current oral contraceptive use
* Current pregnancy
* Chemotherapy for malignancy within past 2 years

Primary outcomes:
measure: CKD progression as measured by changes in GFR and cardiovascular risk as measured by CRP over a 5 year period
timeFrame: 5 years
Secondary outcomes:
measure: insulin resistance
timeFrame: 5 years
Other outcomes:
Locations:
city: Chicago
country: United States
facility: The University of Chicago
state: Illinois
Study officials:
affiliation: University of Chicago
name: Eve Van Cauter, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01219374: Study of Ovum Donors After Donation
Official title: A Longitudinal Prospective Study of Ovum Donors After Donation
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Anonymous Donors
Keywords: egg donor
Lead sponsor: Reproductive Medicine Associates of New Jersey
Sponsor class: OTHER
First posted: 2010-10-13
Enrollment: 500
Sex: FEMALE
Minimum age (years): 21
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Anonymous egg donors

Brief summary: To explore the attitudes and reactions of ovum donors prospectively after ovum donation and to follow their medical histories.

Detailed description: Although several studies have explored donor's reactions and experiences up to a year post donation, no study has explored how donor attitudes and reactions change over time. Currently, there is no long-term data available to describe donor's feelings and reactions to their donation. Consequently, programs have no guidance to counsel prospective donors about whether donors' attitudes change towards their own participation, contact with any offspring, or concerns about the donation. In addition, just as ovum donors' initial health histories were shared anonymously with the recipient(s), any updated information gathered in this study would be shared anonymously with the recipient(s) or offspring should they request those updates.

Eligibility criteria: All anonymous egg donors are eligible for participation.

Primary outcomes:
measure: Do recipients' attitudes and reactions change over time regarding the selection criteria for their donors?
timeFrame: 12-15 Months
Secondary outcomes:
Other outcomes:
Locations:
city: Morristown
country: United States
facility: Reproductive Medicine Associates of New Jersey
state: New Jersey
Study officials:
affiliation: Reproductive Medicine Associates of New Jersey
name: Andrea M Braverman, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05731674: Varied Practice on LAPSIM
Official title: Random Selection of Exercises Versus Self-Directed Training, for Laparoscopic Simulator Training - a Randomized Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Skilss Acquisition for Virtual Reality Laparoscopic Training
Lead sponsor: Copenhagen Academy for Medical Education and Simulation
Sponsor class: OTHER
First posted: 2023-02-16
Enrollment: 36
Sex: ALL
Minimum age (years): 18
Maximum age (years): 99
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: To investigate whether training using a random selection of exercises on a laparoscopic virtual reality simulator results in a stronger retention of skills when using a proficiency-based training program compared to conventional self-directed training.


Eligibility criteria: Inclusion Criteria:

* Medical Students enrolled at a Danish University

Exclusion Criteria:

* Not being enrolled at a medical program at a Danish University, having participated in other virtual reality studies regarding laparoscopy, have had training or practice in laparoscopy on either pigs or in the clinic, have any medical conditions that may hinder a standard learning process when it comes to skills acquisition (eg. parkinson's disease, limited eye-sight etc).

Primary outcomes:
measure: Time (minutes) to reach the predefined proficiency settings for the basic skills and the procedural module after 3-6 weeks without laparoscopic training.
timeFrame: 6 weeks
Secondary outcomes:
measure: Time (minutes) to reach the predefined proficiency settings for the basic skills
timeFrame: 6 weeks
measure: Time (minutes) to reach proficiency setting for the procedural module (salpingectomy due to an ectopic bleeding)
timeFrame: 6 weeks
Other outcomes:
Locations:
city: Copenhagen
country: Denmark
facility: CAMES
Study officials:
References:
Clinical trial NCT00721474: Study to Determine the Effect of a High-Fat Meal on the Relative Bioavailability and Pharmacokinetics of a Single Dose of Bosutinib Administered Orally to Healthy Subjects
Official title: An Open-Label, Randomized, Single-Dose, 2-Period Crossover Study to Determine the Effect of a High-Fat Meal on the Relative Bioavailability and Pharmacokinetics of a Single Dose of Bosutinib Administered Orally to Healthy Subjects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy Subjects
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer
Sponsor class: INDUSTRY
First posted: 2008-07-24
Enrollment: 24
Sex: ALL
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: A Study to determine if a high-fat meal has an effect on the pharmacokinetics of bosutinib.


Eligibility criteria: Inclusion Criteria:

* Healthy men, age 18-50;
* Healthy women of nonchildbearing potential, age 18-50.

Exclusion Criteria:

Primary outcomes:
measure: Pharmacokinetics (plasma concentrations)
timeFrame: 4 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Tacoma
country: United States
state: Washington
Study officials:
affiliation: Wyeth is now a wholly owned subsidiary of Pfizer
name: Medical Monitor
role: STUDY_DIRECTOR
References:
Clinical trial NCT01884974: A Case Control Study of the Prevalence of Pulmonary Hypertension in Patients With Myeloproliferative Diseases.
Official title: A Case Control Study of the Prevalence of Pulmonary Hypertension in Patients With Myeloproliferative Diseases, and Correlation Between Patients Epidemiologic and Clinical Status and the Development of Pulmonary Hypertension.
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Myeloproliferative Disease
Pulmonary Hypertension
Keywords: Myeloproliferative disease
Pulmonary Hypertension
Lead sponsor: Carmel Medical Center
Sponsor class: OTHER
First posted: 2013-06-24
Enrollment: 150
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: patients diagnosed with Myeloproliferative disease and followed up at the Carmel Hematology Unit

Brief summary: Pulmonary hypertension (PH) is defined as a group of diseases characterised by an elevated mean pulmonary artery pressure (Ppa) ≥25 mmHg at rest. Recently, chronic myeloproliferative diseases (CMPD) associated with pulmonary hypertension were included in the group 5 category, corresponding to PH for which the aetiology is unclear and/or multifactorial. CMPD include chronic myelogenous leukaemia, chronic neutrophilic leukaemia and chronic eosinophilic leukaemia (which primarily express a myeloid phenotype and polycythaemia vera), idiopathic myelofibrosis, and essential thrombocytosis in which erythroid or megakaryocytic hyperplasia predominates.

The purpose of this research:

1. Assess Prevalence of PH in patients with CMPD in Northern Israel
2. Describe the demographics and clinical course in patients with CMPD who are diagnosed with PH.

Detailed description: study will include the following:

* sex
* age
* BMI
* ethnicity
* age diagnosed with Myeloproliferative disease
* clinical manifestations of the myeloproliferative disease
* JAK2 mutation
* known hematological complications

Eligibility criteria: Inclusion Criteria:

1) consenting patients diagnosed with a myeloproliferative disease

Exclusion Criteria:

1) Refusal to have an echocardiogram or answer the St. George respiratory questionnaire

Primary outcomes:
measure: pulmonary hypertension
timeFrame: 1 year
Secondary outcomes:
measure: St George Respiratory Questionnaire
timeFrame: 1 year
Other outcomes:
Locations:
city: Haifa
country: Israel
facility: Pulmonology Institute, Carmel Medical Center
Study officials:
affiliation: Carmel Medical Center
name: Shoshan Perek, MD
role: PRINCIPAL_INVESTIGATOR
References: